What Is VK2735? Structure, Research and Status

VK2735 is an investigational peptide from Viking Therapeutics that activates both the GLP-1 and GIP receptors, and FDA has not approved it.

Basics10 min read

Key takeaway

VK2735 is a peptide designed to activate the receptors for two gut hormones, GLP-1 and GIP. Its full chemical structure has not been published. In the 13-week Phase 2 VENTURE trial of 176 adults with obesity or overweight, all four dose groups lost more weight than placebo. Gastrointestinal events were the most common adverse events. Phase 3 trials are underway, and FDA has not approved it.

At a glance

Article typeBasics
Main guideTirzepatide: complete guide
Regulatory statusFDA-approved“Tirzepatide is the first FDA-approved dual agonist” (Tirzepatide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited3 in this article · 48 across 20 articles on Tirzepatide
ProductTirzepatide product page

What is VK2735 is a common question because it belongs to the same receptor class as tirzepatide. Viking Therapeutics, a San Diego company, is testing it in four Phase 3 trials. So far, one human trial of VK2735 has been published in a peer-reviewed journal.

Quick answer: VK2735 is an experimental drug, not an approved medicine. It is a dual agonist of the receptors for GLP-1 and GIP, two gut hormones involved in blood sugar and appetite. Viking Therapeutics owns it and is developing an injectable and a tablet formulation for obesity. Viking describes itself as a clinical-stage company.

Is VK2735 a peptide?

Yes. The ClinicalTrials.gov record for the VENTURE trial describes VK2735 as "a peptide GLP-1 and GIP dual agonist" (NCT06068946). Vitrapep's guide to what peptides are explains the general category.

Little else about its structure is public. The published VENTURE paper says the peptide "contains a side chain that imparts an extended half-life" (Bays et al., 2026). It gives no amino acid sequence, molecular formula or molecular weight. A PubChem name search on November 18, 2026, found no compound record with a structure for VK2735.

The same paper reports receptor binding values, citing unpublished Viking data. VK2735 had an IC50 of 188 nM at the GLP-1 receptor and 325 nM at the GIP receptor. IC50 is the concentration that displaces half of a labeled tracer in a binding assay; lower values mean tighter binding.

Tirzepatide, an approved medicine in this class, has a fully disclosed structure. Table 1 compares the published facts.

Table 1

Is VK2735 a peptide

FeatureVK2735TirzepatideSource
DeveloperViking TherapeuticsEli Lilly and CompanyViking, 2026b; Zepbound label
Molecule typePeptide with a side chain that extends half-lifePeptide based on the GIP sequence, with a C20 fatty diacidBays et al., 2026; Zepbound label
Published formula and weightNot found in the sources reviewedC225H348N48O68; 4813.53 DaZepbound label
Furthest stagePhase 3 trialsFDA-approvedClinicalTrials.gov; Drugs@FDA
First US approvalNone2022 (Mounjaro); Zepbound in 2023Drugs@FDA
Rodent thyroid tumor dataNone found in published sourcesThyroid C-cell tumors in rats; boxed warningZepbound label

Who developed VK2735?

Viking Therapeutics, a San Diego company, calls VK2735 a "wholly owned" dual agonist (Viking, 2026b).

The first registered human study began in December 2021 (NCT05203237). This Phase 1 trial enrolled 92 healthy adults, some with a raised body mass index (BMI). It tested an injectable form and, in a separate part, a tablet form. No posted results or PubMed paper were found for it.

The Phase 2 VENTURE trial followed in August 2023. Viking says it started the Phase 3 VANQUISH program in June 2025, after VENTURE and feedback from FDA.

How is VK2735 designed to work?

VK2735 targets the receptors for two incretins. Incretins are gut hormones, released after eating, that increase insulin release when blood sugar is high. Vitrapep explains each hormone in what is GLP-1 and what is GIP.

The idea of one peptide acting on both receptors predates VK2735. In 2013, Finan and colleagues reported a peptide built from an intermixed sequence of GLP-1 and GIP. It lowered blood sugar more than selective GLP-1 agonists in rodent models, monkeys and humans (Finan et al., 2013). In obese rodents it reduced fat mass, while a GIP-only agonist had little effect on weight.

Lilly described tirzepatide, a fatty acid modified dual agonist, in 2018. In mice it lowered body weight and food intake more than a GLP-1 receptor agonist alone (Coskun et al., 2018).

The Zepbound label says nonclinical studies suggest GIP "may further contribute to the regulation of food intake." Vitrapep's article on the tirzepatide dual-agonist mechanism covers that molecule in depth.

Whether VK2735 signals the same way is not shown in published data. The VENTURE paper cites its preclinical findings as unpublished. A PubMed search on November 18, 2026, found no peer-reviewed animal or cell study of VK2735.

What did the VENTURE trial find?

VENTURE is the only VK2735 trial with peer-reviewed results. It was a Phase 2, randomized, double-blind, placebo-controlled trial at 20 US sites (Bays et al., 2026). It ran from August 31, 2023, to February 23, 2024.

The trial enrolled 176 adults with obesity, or with overweight plus at least one weight-related condition. People with diabetes were excluded. Most were women, with a mean age of about 50. Participants were randomized to four VK2735 dose groups or placebo, about 35 per group, for 13 weeks. All groups received diet and exercise counseling.

The primary endpoint was percent change in body weight at week 13. Viking sponsored the trial, and three of the ten authors listed Viking as their affiliation.

These are human findings from one short Phase 2 trial:

  • Mean body weight fell 9.1% in the lowest dose group and 14.7% in the highest, versus 1.7% with placebo. Each dose group differed from placebo with p < 0.0001.
  • Of treated participants, 93% (130 of 140) lost at least 5% of body weight, versus 12% (4 of 34) with placebo.
  • The share losing at least 10% ranged from 40% to 89% across dose groups, versus 3% with placebo.
  • Of 74 treated participants with prediabetes at the start, 58 (78%) met the study's normal glucose definition at week 13. For placebo, the figure was 4 of 14.
  • HbA1c fell by 0.27 to 0.36 percentage points in the dose groups. It rose by 0.03 points with placebo.

The limits are clear. It was a short dose-finding study with small groups, not powered to compare groups on most measures. Weight was still falling at week 13.

The authors also cited week-12 figures from semaglutide and tirzepatide trials. Separate trials differ in population and methods, so such comparisons cannot rank drugs. Vitrapep's guide on how to evaluate peptide research explains why.

What other VK2735 trials are registered?

Table 2 lists every VK2735 trial found on ClinicalTrials.gov on November 18, 2026. All are Viking-sponsored and placebo-controlled.

Table 2

What other VK2735 trials are registered

TrialPhase and designPopulation and sizeLengthStatus
NCT05203237Phase 1; single and multiple ascending doses92 healthy adultsUp to four weeksCompleted 2024; no results found
VENTURE, NCT06068946Phase 2; injectable; four dose groups176 adults without diabetes13 weeksPublished 2026
VENTURE Oral Dosing, NCT06828055Phase 2; tablet; six dose groups280 adults13 weeksCompleted 2025; not published
NCT07838740Phase 1; maintenance regimensEstimated 270 adults33 weeksRecruiting
VANQUISH-1, NCT07104500Phase 3; injectableAbout 4,500 adults without type 2 diabetes78 weeksEnrolled; primary completion July 2027 (est.)
VANQUISH-2, NCT07104383Phase 3; injectableAbout 1,000 adults with type 2 diabetes78 weeksEnrolled; primary completion July 2027 (est.)
SUNRISE-1, NCT07868835Phase 3; tabletTarget 560 adults without type 2 diabetes68 weeksRecruiting; primary completion July 2028 (est.)
SUNRISE-2, NCT07868939Phase 3; tabletTarget 560 adults with type 2 diabetes68 weeksRecruiting; primary completion October 2028 (est.)

Enrollment in VANQUISH-1 was completed in November 2025, and VANQUISH-2 in March 2026 (Viking, 2026a). The company expects both to finish in 2027.

Viking has announced topline results from the tablet Phase 2 trial and part one of the maintenance study. No peer-reviewed paper or registry results were found for either, so this page does not report those figures. Vitrapep's guide on how to find a peptide clinical trial explains how to read these records.

What side effects were reported for VK2735?

Only VENTURE has published safety data, from 175 treated participants over 13 weeks (Bays et al., 2026). Groups this small can miss uncommon events. Table 3 shows selected events; ranges span the four dose groups.

Table 3

What side effects were reported for VK2735

Event in VENTUREPlacebo (35)VK2735 dose groups (35 each)
Any adverse event69%71% to 91%
Nausea20%26% to 63%
Constipation11%20% to 29%
Diarrhea9%11% to 31%
Vomiting0%9% to 29%
Gastroesophageal reflux3%6% to 17%
Decreased appetite0%6% to 26%
Injection site reactions9%6% to 14%
Adverse event leading to stopping study drug0%3% to 20%
Serious adverse events3%3% to 6%
Anti-drug antibodies at week 13Not reported9% to 23%

Most drug-related events were mild or moderate. Eight participants (4.6%) had a severe drug-related event, and none had a life-threatening one. Gastrointestinal events occurred mostly early and became less frequent over time.

Eight participants had 12 serious adverse events. Investigators judged ten unrelated to the drug. One participant had atrial fibrillation, judged possibly related, and dehydration, judged probably related. One participant died of head trauma after a fall, which was judged unrelated.

No pancreatitis was reported. Two participants had gallbladder events, cholecystitis or gallstones. Mean heart rate rose by 3.3 to 9.3 beats per minute in the dose groups, versus 1.4 with placebo. The paper does not say whether the anti-drug antibodies affected safety or response.

VK2735 has no FDA label, so no boxed warning or label-based safety list exists. Its long-term and rodent tumor data are unpublished. By contrast, the Zepbound label carries a boxed warning on thyroid C-cell tumors seen in rats.

What is VK2735's regulatory status?

FDA has not approved VK2735, and Drugs@FDA lists no product containing it. There is no approved label and no FDA-reviewed dose. Viking calls its four Phase 3 trials registration studies, meaning trials intended to support an application for approval.

FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, does not name VK2735. It says FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled "for research purposes" (FDA, 2026). FDA adds that unapproved versions are not reviewed for safety, effectiveness or quality.

In sport, the WADA 2026 Prohibited List does not name VK2735 or any GLP-1 or GIP receptor agonist. Its S0 section bans at all times any substance not covered elsewhere and lacking government approval for human therapeutic use. WADA gives "drugs under pre-clinical or clinical development" as an example.

Vitrapep does not sell VK2735; this page is a reference summary of published research and regulatory information. A research-use label on any product does not make it an approved medicine or legal for people. See research peptides and human-use risks.

How does VK2735 relate to tirzepatide?

Both are peptides that activate the GLP-1 and GIP receptors. Tirzepatide is approved as Mounjaro (2022) and Zepbound (2023). VK2735 is still in trials. Vitrapep's tirzepatide complete guide covers the approved medicine.

No published trial has compared the two directly; all registered VK2735 trials use placebo. Shared receptor targets do not mean shared effects or safety, because structure shapes how long a peptide lasts and how it binds. Until the Phase 3 results are published, the two cannot be ranked.

Frequently asked questions

Is VK2735 FDA-approved?

No. FDA has not approved VK2735 for any use. It is in Phase 3 trials.

Is VK2735 a peptide?

Yes. Its trial records describe it as a peptide GLP-1 and GIP dual agonist. Its amino acid sequence and formula were not found in published sources.

Is VK2735 the same as tirzepatide?

No. They act on the same two receptors but are different molecules. Tirzepatide is FDA-approved; VK2735 is not.

How much weight did VENTURE participants lose?

Mean weight fell 9.1% to 14.7% across the four dose groups over 13 weeks, versus 1.7% with placebo. The trial was short and small.

What side effects were reported for VK2735?

In VENTURE, the most common were nausea, constipation, diarrhea and vomiting. Most were mild or moderate and occurred early.

When could Phase 3 results be available?

Viking expects the VANQUISH trials to finish in 2027, with primary completion estimated for July 2027.

Is VK2735 prohibited in sport?

WADA's 2026 list does not name it. The list's S0 section covers unapproved substances, including drugs still in clinical development.

What to know now

  • VK2735 is an investigational peptide from Viking Therapeutics that targets the GLP-1 and GIP receptors.
  • Its sequence and formula have not been published; the VENTURE paper describes only a half-life-extending side chain.
  • In one 13-week Phase 2 trial, all dose groups lost more weight than placebo, with mostly gastrointestinal adverse events.
  • FDA has not approved VK2735, and four placebo-controlled Phase 3 trials are underway.

What we’re watching

  • VANQUISH-1 (NCT07104500) and VANQUISH-2 (NCT07104383), both with primary completion estimated for July 2027.
  • SUNRISE-1 (NCT07868835) and SUNRISE-2 (NCT07868939), the tablet Phase 3 trials, now recruiting.
  • Peer-reviewed publication or registry results for the tablet Phase 2 trial and the maintenance study.
  • Publication of VK2735's structure and preclinical data, which the VENTURE paper cites as unpublished.

Also in the library

More for endocrine & metabolism

All 48 compounds for endocrine & metabolism

Sources: Bays 2026, Obesity, 34; Viking Therapeutics 2023; Viking Therapeutics 2022; Viking Therapeutics 2025; Viking Therapeutics 2025; Viking Therapeutics 2025; Viking Therapeutics 2026a; Viking Therapeutics 2026b; Eli Lilly and Company 2026; U.S. Food and Drug Administration 2026; Finan 2013, Science Translational Medicine, 5; Coskun 2018, Molecular Metabolism, 18; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2025. All 14 citations

Back to the research library

References

  1. Bays, H. E., Toth, P., Alkhouri, N., Pullman, J., Freilich, B., Neutel, J., et al. (2026). Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: Phase 2, randomized, 13-week VENTURE study. Obesity, 34(3), 537-549. https://pubmed.ncbi.nlm.nih.gov/41508550/
  2. Viking Therapeutics. (2023). VK2735 for weight management Phase 2 (VENTURE). ClinicalTrials.gov identifier NCT06068946. https://clinicaltrials.gov/study/NCT06068946
  3. Viking Therapeutics. (2022). Phase 1 study to evaluate the safety and tolerability of VK2735. ClinicalTrials.gov identifier NCT05203237. https://clinicaltrials.gov/study/NCT05203237
  4. Viking Therapeutics. (2025). VK2735 for weight management Phase 2 (VENTURE Oral Dosing). ClinicalTrials.gov identifier NCT06828055. https://clinicaltrials.gov/study/NCT06828055
  5. Viking Therapeutics. (2025). VK2735 for weight management Phase 3 (VANQUISH 1). ClinicalTrials.gov identifier NCT07104500. https://clinicaltrials.gov/study/NCT07104500
  6. Viking Therapeutics. (2025). VK2735 for weight management type 2 diabetes Phase 3 (VANQUISH 2). ClinicalTrials.gov identifier NCT07104383. https://clinicaltrials.gov/study/NCT07104383
  7. Viking Therapeutics. (2026a, March 26). Viking Therapeutics announces completion of enrollment in Phase 3 VANQUISH-2 trial of VK2735 [Press release]. https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735
  8. Viking Therapeutics. (2026b, October 28). Viking Therapeutics reports third quarter 2026 financial results and provides corporate update [Press release]. https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update
  9. Eli Lilly and Company. (2026). ZEPBOUND (tirzepatide) injection prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  10. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 215866, Mounjaro (tirzepatide). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
  11. Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., et al. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine, 5(209), 209ra151. https://pubmed.ncbi.nlm.nih.gov/24174327/
  12. Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14. https://pubmed.ncbi.nlm.nih.gov/30473097/
  13. U.S. Food and Drug Administration. (2026, October 1). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  14. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf